These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 32451850)

  • 1. Clinical implications of assessment of apixaban levels in elderly atrial fibrillation patients: J-ELD AF registry sub-cohort analysis.
    Suzuki S; Yamashita T; Akao M; Okumura K;
    Eur J Clin Pharmacol; 2020 Aug; 76(8):1111-1124. PubMed ID: 32451850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter prospective cohort study to investigate the effectiveness and safety of apixaban in Japanese elderly atrial fibrillation patients (J-ELD AF Registry).
    Okumura K; Yamashita T; Suzuki S; Akao M;
    Clin Cardiol; 2020 Mar; 43(3):251-259. PubMed ID: 31737921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Outcomes of Very Elderly Patients With Atrial Fibrillation Receiving On-label Doses of Apixaban: J-ELD AF Registry Subanalysis.
    Okada M; Inoue K; Tanaka N; Sakata Y; Akao M; Yamashita T; Suzuki S; Okumura K;
    J Am Heart Assoc; 2021 Aug; 10(15):e021224. PubMed ID: 34323123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes according to dose reduction criteria of apixaban in Japanese elderly patients with atrial fibrillation: J-ELD AF Registry subanalysis.
    Akao M; Yamashita T; Suzuki S; Okumura K;
    Heart Vessels; 2021 Jul; 36(7):1035-1046. PubMed ID: 33486555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study design of J-ELD AF: A multicenter prospective cohort study to investigate the efficacy and safety of apixaban in Japanese elderly patients.
    Akao M; Yamashita T; Okumura K;
    J Cardiol; 2016 Dec; 68(6):554-558. PubMed ID: 26803550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Low Body Weight with Clinical Outcomes in Elderly Atrial Fibrillation Patients Receiving Apixaban-J-ELD AF Registry Subanalysis.
    Kadosaka T; Nagai T; Suzuki S; Sakuma I; Akao M; Yamashita T; Anzai T; Okumura K;
    Cardiovasc Drugs Ther; 2022 Aug; 36(4):691-703. PubMed ID: 33830400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of creatinine clearance on clinical outcomes in elderly atrial fibrillation patients receiving apixaban: J-ELD AF Registry subanalysis.
    Akao M; Yamashita T; Suzuki S; Okumura K;
    Am Heart J; 2020 May; 223():23-33. PubMed ID: 32135338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age-Related Differences in the Clinical Characteristics and Treatment of Elderly Patients With Atrial Fibrillation in Japan　- Insight From the ANAFIE (All Nippon AF In Elderly) Registry.
    Hiasa KI; Kaku H; Inoue H; Yamashita T; Akao M; Atarashi H; Koretsune Y; Okumura K; Shimizu W; Ikeda T; Toyoda K; Hirayama A; Yasaka M; Yamaguchi T; Teramukai S; Kimura T; Kaburagi J; Takita A; Tsutsui H
    Circ J; 2020 Feb; 84(3):388-396. PubMed ID: 31969518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation.
    Ueshima S; Hira D; Fujii R; Kimura Y; Tomitsuka C; Yamane T; Tabuchi Y; Ozawa T; Itoh H; Horie M; Terada T; Katsura T
    Pharmacogenet Genomics; 2017 Sep; 27(9):329-336. PubMed ID: 28678049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and effectiveness of apixaban in comparison to warfarin in patients with nonvalvular atrial fibrillation: a propensity-matched analysis from Japanese administrative claims data.
    Kohsaka S; Katada J; Saito K; Terayama Y
    Curr Med Res Opin; 2018 Sep; 34(9):1627-1634. PubMed ID: 29772946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes.
    Hylek EM; Held C; Alexander JH; Lopes RD; De Caterina R; Wojdyla DM; Huber K; Jansky P; Steg PG; Hanna M; Thomas L; Wallentin L; Granger CB
    J Am Coll Cardiol; 2014 May; 63(20):2141-2147. PubMed ID: 24657685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study.
    Staerk L; Gerds TA; Lip GYH; Ozenne B; Bonde AN; Lamberts M; Fosbøl EL; Torp-Pedersen C; Gislason GH; Olesen JB
    J Intern Med; 2018 Jan; 283(1):45-55. PubMed ID: 28861925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and effectiveness of reduced-dose apixaban in Japanese patients with nonvalvular atrial fibrillation in clinical practice: A sub-analysis of the STANDARD study.
    Inoue H; Umeyama M; Yamada T; Hashimoto H; Komoto A; Yasaka M
    J Cardiol; 2020 Feb; 75(2):208-215. PubMed ID: 31421933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity matched analysis of administrative claims data.
    Kohsaka S; Murata T; Izumi N; Katada J; Wang F; Terayama Y
    Curr Med Res Opin; 2017 Nov; 33(11):1955-1963. PubMed ID: 28857611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measurement of Anti-Factor Xa Activity in Patients on Apixaban for Non-Valvular Atrial Fibrillation.
    Osanai H; Ajioka M; Masutomi T; Kuwayama T; Ishihama S; Sakamato Y; Otaka N; Sakaguchi T; Inoue Y; Kanbara T; Nakashima Y; Asano H; Sakai K
    Circ J; 2015; 79(12):2584-90. PubMed ID: 26439323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial.
    Alexander JH; Andersson U; Lopes RD; Hijazi Z; Hohnloser SH; Ezekowitz JA; Halvorsen S; Hanna M; Commerford P; Ruzyllo W; Huber K; Al-Khatib SM; Granger CB; Wallentin L;
    JAMA Cardiol; 2016 Sep; 1(6):673-81. PubMed ID: 27463942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of
    Skripka AI; Krupenin PM; Kozhanova ON; Kudryavtseva AA; Fedina LV; Akmalova KA; Bochkov PO; Sokolova AA; Napalkov DA; Sychev DA
    Drug Metab Pers Ther; 2024 Jun; 39(2):89-97. PubMed ID: 38943286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial.
    Zeitouni M; Giczewska A; Lopes RD; Wojdyla DM; Christersson C; Siegbahn A; De Caterina R; Steg PG; Granger CB; Wallentin L; Alexander JH;
    J Am Coll Cardiol; 2020 Mar; 75(10):1145-1155. PubMed ID: 32164888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 20. Apixaban for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: The PAROS cross-sectional study of routine clinical practice.
    Falissard B; Picard F; Mahe I; Hanon O; Touzé E; Danchin N; Lamy FX; Ricci L; Steg PG
    Arch Cardiovasc Dis; 2019; 112(6-7):400-409. PubMed ID: 31014991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.